GSK plc (GSK) executives add stock via Share Reward Plan and dividend reinvestment

Rhea-AI Filing Summary

GSK plc reports multiple acquisitions of its ordinary shares of 31 ¼ pence each (ISIN GB00BN7SWP63) by senior management and persons closely associated with them. These transactions occurred on 9 July 2026 on the London Stock Exchange at prices around £19.6290 per share.

Lynn Baxter (President, Europe), Julie Brown (Chief Financial Officer), James Ford (SVP and Group General Counsel), David Redfern (President, Corporate Development), Regis Simard (President, Global Supply Chain), Philip Thomson (President, Global Affairs), Deborah Waterhouse (CEO, ViiV Healthcare and President, Global Health), Victoria Whyte (SVP & Company Secretary), and PCA Neil Falkingham each acquired small share amounts under GSK’s Share Reward Plan, typically 12–14 shares per person combining partnership and matching shares.

In addition, Luke Miels (Chief Executive Officer) and several of the same executives and PCAs acquired further ordinary shares through the re-investment of dividends paid on 9 July 2026 on holdings within the Share Reward Plan, with individual acquisitions ranging from a few shares to over 1,000 shares in a single transaction.

Key Figures

Share acquisition price (plan): £19.6290 per share Typical plan allocation: 12 ordinary shares Plan allocation (Victoria Whyte): 14 ordinary shares +5 more

8 metrics

Share acquisition price (plan) £19.6290 per share Price for most Share Reward Plan and dividend reinvestment acquisitions on 9 July 2026

Typical plan allocation 12 ordinary shares 6 partnership shares and 6 matching shares granted to many participants

Plan allocation (Victoria Whyte) 14 ordinary shares 7 partnership shares and 7 matching shares under the Share Reward Plan

Dividend reinvestment (CEO Luke Miels) 3 ordinary shares Acquired at £19.6290 through dividend re-investment on 9 July 2026

Dividend reinvestment (Lynn Baxter) 34 ordinary shares Acquired at £19.6290 via re-investment of dividends in the Share Reward Plan

Dividend reinvestment (David Redfern) 70 ordinary shares Acquired at £19.6290 via dividend re-investment in the Share Reward Plan

Dividend reinvestment (Victoria Whyte) 216 ordinary shares Acquired at £19.6297 following dividend re-investment on 9 July 2026

Dividend reinvestment (Iain Whyte) 1,050 ordinary shares Acquired at £19.6297 as a person closely associated with Victoria Whyte

Key Terms

PDMR, person closely associated, Share Reward Plan, re-investment of dividends, +1 more

5 terms

PDMR regulatory

"Details of PDMR/person closely associated with them (‘PCA’)"

A PDMR (person discharging managerial responsibilities) is an individual who can shape a company’s strategy or finances—typically senior executives, board members, or close advisors with decision-making authority. Investors care because PDMRs often hold material, non‑public information and their buying or selling of shares must be reported; monitoring those disclosures is like watching a ship’s captain to read the likely course and spot possible insider risk.

person closely associated regulatory

"Details of PDMR/person closely associated with them (‘PCA’)"

Share Reward Plan financial

"Acquisition of Ordinary Shares under the Company’s Share Reward Plan"

re-investment of dividends financial

"Acquisition of Ordinary Shares following the re-investment of dividends paid"

ordinary shares of 31 ¼ pence each financial

"Description of the financial instrument | Ordinary shares of 31 ¼ pence each"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 07/13/2026 - 11:28 AM Accepted by SEC EDGAR 07/13/2026 - 11:28 AM Learn about SEC filing dates

FAQ

What insider share transactions did GSK (GSK) disclose in this Form 6-K?

GSK disclosed that multiple senior managers and persons closely associated with them acquired ordinary shares on 9 July 2026, mainly via the Company’s Share Reward Plan and dividend re-investment on shares held in that plan.

Which GSK (GSK) executives acquired shares under the Share Reward Plan?

Executives including Lynn Baxter, Julie Brown, James Ford, David Redfern, Regis Simard, Philip Thomson, Deborah Waterhouse and Victoria Whyte acquired small amounts of GSK ordinary shares under the Company’s Share Reward Plan on 9 July 2026.

At what price were the GSK (GSK) insider share acquisitions executed?

Most acquisitions were executed at £19.6290 per share for GSK ordinary shares; two transactions by Victoria and Iain Whyte used a price of £19.6297 per share, all on the London Stock Exchange on 9 July 2026.

How many GSK (GSK) shares did insiders typically receive under the Share Reward Plan?

For many participants, the Share Reward Plan granted 6 partnership shares and 6 matching shares, totaling 12 ordinary shares each, while one grant to Victoria Whyte comprised 7 partnership and 7 matching shares, totaling 14 shares.

Did GSK’s (GSK) CEO participate in dividend re-investment share acquisitions?

Yes. Chief Executive Officer Luke Miels acquired 3 ordinary shares at £19.6290 each through the re-investment of dividends paid on 9 July 2026 on shares held in the Share Reward Plan.

Which GSK (GSK) person closely associated with an executive made the largest disclosed acquisition?

Person closely associated Iain Whyte, linked to Victoria Whyte (SVP & Company Secretary), acquired 1,050 ordinary shares of GSK at £19.6297 each on 9 July 2026 through dividend re-investment.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the ‘Company’)

Transaction notification

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Lynn Baxter
b)	Position/status	President, Europe
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	6 (partnership shares)
			£19.6290	6 (matching shares)
		d)	Aggregated information
Aggregated volume Price	12 Ordinary Shares £19.6290
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Julie Brown
b)	Position/status	Chief Financial Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	6 (partnership shares)
			£19.6290	6 (matching shares)
		d)	Aggregated information
Aggregated volume Price	12 Ordinary Shares £19.6290
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	6 (partnership shares)
			£19.6290	6 (matching shares)
		d)	Aggregated information
Aggregated volume Price	12 Ordinary Shares £19.6290
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	David Redfern
b)	Position/status	President, Corporate Development
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	6 (partnership shares)
			£19.6290	6 (matching shares)
		d)	Aggregated information
Aggregated volume Price	12 Ordinary Shares £19.6290
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	6 (partnership shares)
			£19.6290	6 (matching shares)
		d)	Aggregated information
Aggregated volume Price	12 Ordinary Shares £19.6290
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Philip Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	6 (partnership shares)
			£19.6290	6 (matching shares)
		d)	Aggregated information
Aggregated volume Price	12 Ordinary Shares £19.6290
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	6 (partnership shares)
			£19.6290	6 (matching shares)
		d)	Aggregated information
Aggregated volume Price	12 Ordinary Shares £19.6290
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Victoria Whyte
b)	Position/status	SVP & Company Secretary
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	7 (partnership shares)
			£19.6290	7 (matching shares)
		d)	Aggregated information
Aggregated volume Price	14 Ordinary Shares £19.6290
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Neil Falkingham
b)	Position/status	PCA of Lynn Baxter (President, Europe)
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	6 (partnership shares)
			£19.6290	6 (matching shares)
		d)	Aggregated information
Aggregated volume Price	12 Ordinary Shares £19.6290
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Luke Miels
b)	Position/status	Chief Executive Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on shares held through the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	3
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Lynn Baxter
b)	Position/status	President, Europe
c)	Initial notification /amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on shares held through the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	34
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on shares held through the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	11
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	David Redfern
b)	Position/status	President Corporate Development
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on shares held through the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	70
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on shares held through the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	28
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Philip Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on shares held through the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	45
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on shares held through the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	58
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Victoria Whyte
b)	Position/status	SVP & Company Secretary
c)	Initial notification /amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on shares held through the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	54
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Neil Falkingham
b)	Position/status	PCA of Lynn Baxter (President, Europe)
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on shares held through the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6290	57
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Victoria Whyte
b)	Position/status	SVP & Company Secretary
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6297	216
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Iain Whyte
b)	Position/status	PCA of Victoria Whyte (SVP & Company Secretary)
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£19.6297	1,050
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-07-09
f)	Place of the transaction	London Stock Exchange (XLON)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: July 13, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc